Introduction
Dravet syndrome (DS) is a severe childhood-onset epileptic encephalopathy caused by SCN1A mutations [1] . However, it was recently reported that this syndrome can sometimes also be caused by STXBP1 mutations [2] .
The first signs of the disease mostly occur between the first and the eighth month of life, and only rarely after the first year of life. Seizures can occur in the context of underrecognized fever, although an afebrile first manifestation is seen in as many as 32-58% of patients. Initial psychomotor development is often normal, but then usually stagnates in the second year of life [1] .
A specific motor phenotype was recently described in a group of DS adults, characterized by antecollis, parkinsonian gait, other parkinsonian features, and brief psychotic disorders.
The treatment is challenging due to the poor response to pharmacotherapy. Cannabidiol may be an option for this devastating disease, although evidence of its effectiveness is still limited.
Case report
We here report regarding a 19-year-old woman with a history of epilepsy since infancy. She had no family history and she exhibited appropriate development of psychomotor milestones until two years of age. She had her first generalized seizure at the age of six months, which occurred when she was feverish due to a viral infection. Two years later, she suffered a brief episodes of loss of head muscle tone (dropped head). Brain MRI (magnetic resonance imaging) did not reveal structural lesions and repeated electroencephalograms yielded non-specific recordings with variable graphs, such as spikes-waves, poly-spikes, or sharp waves (Fig. 1) . Then, at 6 years of age, she had multiple generalized seizures, with more than 15 seizures a day, and the delay in her cognitive abilities became more noticeable. Since the age of 13 she has had startle-induced episodes as myoclonus that could be triggered by sound and tactile stimuli.
The patient is currently being treated with stiripentol, clobazam, valproic acid, and vagus nerve stimulation after having failed to derive a benefit from other treatments.
Over the past year she has presented a striking bradykinesia that impedes her ability to walk (FAC 1 according to the Functional Ambulatory Category gait rating scale), antecollis, mood swings, impulsivity, heteroaggressive behavior, and visual hallucinations.
A range of genetic and metabolic tests came out negative during the diagnostic assessment, among them Sanger sequencing of the SCN1A gene (sodium voltage-gated channel alpha subunit 1). Ultimately, whole exome sequencing revealed a de novo p.Arg406His mutation in the STXBP1 gene (which codes for syntaxin-binding protein 1).
We also administered cannabidiol as adjuvant therapy. Since then, she has experienced a considerable reduction in the number of seizures to less than five seizures a day, and there has also been a striking improvement in her motor abilities. At present, she is able to walk unassisted for more than 100 m (FAC 4). 
Discussion
Dravet syndrome (DS) is a rare and severe epileptic encephalopathy affecting 1/20-40,000 live births [1] . Approximately 75-80% of DS patients have mutations in the SCN1A gene. However, in recent years other genes, such as STXBP1, have been reported to be involved. STXBP1 mutations cause a broad spectrum of epileptic syndromes related to fever, ranging from simple febrile seizures to severe epileptic encephalopathies [2] . Our case is an example of a carrier of an STXBP1 mutation who is prone to febrile seizures.
An adult motor phenotype defined by parkinsonian characteristics was recently described [3] . These patients were identified to be carriers of mutations in the SCN1A gene. The voltage-gated sodium channel is located in the cerebral cortex as well as in the cerebellar cortex and the basal ganglia.
Symptoms such as dysarthria, ataxia, hypomimia, bradykinesia, parkinsonian gait, antecollis, and brief psychotic alterations can arise in adult patients with Dravet syndrome.
According to several reports, the motor phenotype is not related to the number and frequency of seizures, as some patients are seizure-free yet they still exhibit bradykinesia and hypomimia [3] .
We here report regarding an adult with DS caused by mutation of STXBP1 with parkinsonian features, thus showing that the adult motor phenotype is not exclusive to SCN1A mutation. We believe that STXBP1 mutation should be added to the genetic alterations associated with the motor phenotype.
Recognizing this phenotype assists with differentiating adult patients with DS from those affected with Lennox-Gastaut syndrome (LGS), as LGS patients have not been reported to have the motor phenotype with parkinsonian features.
It has been suggested that the parkinsonian characteristics should improve with do-paminergic therapies, although there is no consensus in this regard [3] . Our patient did not require dopamine replacement therapy since her motor symptoms improved once her seizures were controlled with cannabidiol. This finding is of particular interest because, theoretically, the effect of cannabidiol is not directed at these symptoms.
The treatment of DS is complex and multiple anti-epileptic therapies have been used (albeit without yielding any encouraging results), even though it is recommended that certain anticonvulsants that act on the sodium channels are to be avoided because they can result in worse seizures.
Some studies have reported better control of seizures using cannabidiol derivatives. The possible mechanism of action of cannabinoids has not been elucidated. The most likely hypotheses is that there may be an effect on cannabinoid receptor type 1 (CB-1) and the N-methyl-Daspartic acid (NMDA) receptor, although these mechanisms have yet to be confirmed. [4] The precedent for cannabidiol effects on seizures led to it being considered as a treatment option for DS.
Conclusion
Thus, our findings support the notion that STXBP1 mutation can underlie Dravet syndrome in patients who do not have a SCN1A mutation, and that STXBP1 mutation is related to the motor phenotype with parkinsonian features.
Our patient responded well to cannabidiol treatment. The additional effect observed on motor symptoms cannot readily be explained, although we believe that good control of the seizures could have influenced the improvement of these symptoms.
Finally, we cannot draw any definitive conclusions regarding the possible benefit of DS treatment with the cannabidiol as further studies are needed to validate its effectiveness.
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